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In Beebe Plains, Vermont, there is a street,
appropriately named Canusa Avenue, that runs
right along the United States-Canada border.
louses on the northern side of the street are in
Canada while houses on the southern side are
in Vermont. If a resident of the northern side
ot Canusa Avenue needs medication to control
high cholesterol, he or she can purchase a 90-
day supply of 20 milligram Lipitor for $170.
On the southern side of the street, Vennont
residents will have to dig much deeper if they
need to purchase the same drug. The same 90-
day supply of Lipitor costs about $330 in the
United States.
This is not what one would expect to find in the
globalized economy. However, today's global
economic system has seen the acceleration of cross-
border economic, cultural, and political interactions.
These forces hase led to a convergence in the price
of many goods and services. Due to a host of factors,
but especially due to the safety considerations unique
to pharmaceutical drugs and the monumental costs
needed to protect the public health against unhealthy
and ineffective drugs, drugs sold in the United States
escape the equalizing effects of the global economy.
It is estimated that Americans pay between 35% and
55% more for brand name prescription drugs than
people around the world.2 At a time when health care
costs are consuming an increasingly unacceptable
share of U.S. Gross Domestic Product (GDP), public
pressure has mounted for the use of international
market forces in order to lower the price of American
prescription drugs. As the government agency tasked
with regulating prescription drugs, the U.S. Food
and Drug Administration's (FDA) role of ensuring
safety and effectiveness is threatened by legitimate
demands that health- and life-sustaining drugs become
more affordable. The debate on whether to ease the
restrictions on the importation and re-importation
of drugs reflects a struggle to gain access to cheaper
drugs despite the dangers that a relaxation of the
FDVs control over drugs will have on public health.
Although the importation and re-importation of drugs
remains illegal under almost every scenario. otherwise
law-abiding Americans are choosing to ignore the laxx
and potential risks associated with consuming drugs
that have not received FDA approval. The prospect
of alleviating the high cost of health care by purchasing
cheaper drugs has even led states to enthusiastically
flout federal laws barring importation of unapproved
(and thus illegal) drugs.'
Due to the explosion of illegal transactions involving
the purchase of cheaper drugs in Canada by Americans
who seek to transport them into the United States, much
of the debate focuses on re-importation from Canada
and other industrialized nations. Drug re-importation
in the United States "involves [Americansi buying
American-made prescription drugs from countries
to which U.S. pharmaceutical companies export
their products, either by traveling there to buy drugs
or purchasing them through the mail."4 Enforcing
restrictions on the importation of drugs manufactured
in less developed countries, that lack oversight and
inspections by an FDA-equivalent government agency,
fail to spark the same outcry as the ban on re-importation
of drugs from industrialized countries, such as Canada.
The FDA frequently cites concerns about the labeling,
shipping, and handling of drugs imported from Canada
as a policy justification for maintaining the ban on re-
importation.r The proposition that the Canadian drug
supply is less safe has seen effective rebuttals, with
some analyses even concluding that it is safer than
drugs in the United States.6 A more convincing reason
for prohibiting the re-importation of drugs is that the
public health suffers when pharmaceutical companies
are discouraged from researching and developing new
drugs due to the reduced profitability that would follow
re-importation.
This article first provides a summary of the two most
accepted explanations for the stark price differential
betweecn drugs sold in the U nited States and those sold
in thc rest of thc industrializcd sworld, specifically in
C anada. Second, this article sketches an oxverviexx of
how the hF)A regulates domestic drugs and imported
drugs that are FDA approsved. IThird, this article
discusses the laxx applicable to impoited drugs the
FDA did not approve, and to re-imported drugs that
the FDA subjected to its approval process. Finally,
this article concludes by briefly analyzing the political
variables that may affect the future of drug importation
and re-importation.
There are numerous theories advanced to explain why
drug prices in the U'nited States and Canada diverge
so significantly, even among American-manufactured
drugs whose only substantive difference lies in where
they are sold. Although no simple explanation exists,.
the two most common explanations are government
drug price controls and price discrimination.
Unlike the market-driven pharmaceutical industry in
the United States, Canada's Patented Medicine Prices
Review Board (PMPRB3) enlorces price controls on
patented medicines.' The PMPRB is an independent
arm of the Canadian Government that has the power to
"investigate and regulate excessive pricing of patented
pharmaceutical drugs," including levying fines if prices
exceed the allowable amount.' The maximum amount
a pharmaceutical company may charge for patented
drugs is based on the average price of the drug in
seven other developed countries. PMIIR13 regulations
permit patented drug price increases only on a yearly
basis, and only if the increase is proportional to an
increase in the Consumer Price Index (CPI).10 The
PMPRB estimates that Americans pay 67% more for
patented drugs than Canadians do."
Price discrimination may also contribute to the drug
price differences and may even supersede price controls
as the primary cause.1 Price discrimination occurs
when a company charges different prices in different
markets for the same product.1 Price discrimination is
possible when markets are segmented based on certain
factors, such as the disposable income and tastes of
consumers.14 A common example of this phenomenon
at work occurs when movie theaters charge a lower
price for a movie ticket to seniors and students due
to their lower average income relative to the general
population. Aidan Hlollis, a Canadian economist and
proponent of price discrimination as the major factor
drixving pr'icc differences, asserts that pharmaceutical
companies set a lower price in the Canadian market
than they do in the United States, because ot Canadlians'
loxxec income compared to that of fmericans'."
T he FI)A's role as a modern regulatory agency is the
result of the Federal Food, Drug, and Cosmetics Act of
1938 (FDCA). 6 Congress amended the FDCA more





may be described as "technical and remedial," but
the most prominent have significantly altered the
way the FDA regulates and have expanded the depth
and breadth of the FDA's regulatory authority.1 A
notable example is the Medical Device Amendment,
which "transformed its approach to regulation of
[medical devices] and substantially enlarged the
array of regulatory tools available to it."" The FI)A's
regulatory authority, as originally established by the
FDCA, is generally categorized into two concepts:
(I) "adulteration," which pertains to the content of a
product; and (2) "misbranding," which pertains to the
labeling of a product.19 The majority of enforcement
power in the FDCA originates from the adulteration
and misbranding provisions. Through amendments
to the FDCA, the FDA adjusted the definitions of
adulteration and misbranding in order to broaden the
scope of the FDA's regulatory role. The statutorily
prescribed enforcement remedies available to the FDA
include criminal prosecution (in coordination with the
Department of Justice) of individuals and firms who
commit prohibited acts, injunction against such acts,
seizure of adulterated or misbranded goods, and pursuit
of civil penalties for some violations.20 Yet informal
remedies "comprise the primary routine enforcement
tools of the agency."" These tools include recalls,
publicity, and warning letters.
For the FIDA to permit the importation of a foreign-
manufactured drug, it must comply with the same
requirements applicable to domestic drugs in interstate
commerce." The FDA's regulation of drugs is
appropriately referred to as a "closed" system in which
the agency regulates the manufacturing, marketing,
and labeling of every drug legally sold in the United
States. Imported and domestic drugs must satisfy
five requirements, among others. under the FDCA
before they can be legally introduced into interstate
commerce.24 First, a drug is adilterated, and thus
is prohibited from entering interstate commerce, if
it is not produced in accordance with good manu-
facturing practice (GMP).2 Even if a drug is not
"pharmacologically deficient," it is adulterated if it
does not comply with GMP.6 Second, a drug must not
be misbranded, "which, among other things, means
that the labeling must bear the name and address of
the manufacturer, packer, or distributer, and [mustI
not be false or misleading, and that the drug must
be manufactured in an establishment registered with
the FDA under 1l)CA 8510. "Any drug, even a
foreign version of an FDA approved drug, will be an
unapproved drug unless it meets all U.S. packaging,
labeling, and dosage requirements."" Third, a drug
subjecttoFDCA§ 503(b)(1)will be exemptfrom FDCA
§ 502(f)(1), when it is "in the possession of a person
regularly and lawfully engaged in the manufacture,
transportation, storage, or wholesale distribution of
prescription drugs,"2' labeling requirements (e.g., re
Rx Only), and includes a package insert in the precise
language and format approved by FDA.3 Fourth,
"[any imported drug must be dispensed only upon
a valid prescription by a licensed prescriber, and
distributed with a pedigree" except in the case of a
manufacturer orADR." 32 Lastly, and the most onerous
of all the requirements, the FDA must approve the
drug itself.33
FAII"O TeR4DuA roa hocess
As of 2002 it takes an average of 8.5 years and costs
about $500 million to comply with the rigorous FDA
drug review process and subsequently bring a drug to
the consumer." The financial costs and regulatory
risks involved in this review process may help explain
the broad gap between the price of drugs sold in the
U nited States and those sold in other countries. Ihe drug
development process usually begins in laboratories,
wxhere scientists test the effects of chemical compounds
involved in the disease xwhose treatment they seek3>
The chemicals are then tested in txso oi more species
of animals in order to determine wxhether they can be
sately used in humans.' 6 This initial laboratory testing
of chemicals is referrcd to as preclinical research.
If the FD I)finds the approach promising and
an institutional ieviexx boaid of scientists.
ethicists. and health-caie specialists appioves
the sponsor's study protocol, the ding enters a
progression of tests in humans. Iach new trial
phase is predicated on a successful outcome of
the previous one: Phase Jstudies test the product
for its adverse effects on a small number of
healthy volunteers. Phase If studies probe the
drug's effectiveness in patients who have the
disease or condition the product is intended
to treat. Phase I studies seek to determine
the drug's safety, effectiveness and dosage. In
these trials, hundreds or thousands of patients
are randomly assigned to be treated either with
the tested drug or a control substance, most
frequently a placebo.3
The data gathered from these studies and other
infonnation about the drug such as, "what the
ingredients of the drug are, the results of the animal
studies, the way in which the drug behaves in the body,
and how it is manufactured, processed and packaged,"
are then included in a New Drug Application (NDA).31
An NDA is a formal proposal to the FDA to approve
a new pharmaceutical for sale and marketing in
the United States."' Applications for generic drugs,
'a copy that is the same as a brand-name drug in
dosage, safety, strength, the way it is taken, quality,
perfoimance and intended use," 41 come in the form of
an Abbreviated NDA (ANDA). These applications are
"'abbreviated' because they are generally not required
to include preclinical (animal) and clinical (human)
data to establish safety and effectiveness. Instead,
generic applicants must scientifically demonstrate that
their product is bioequivalent (i.e., performs in the
same manner as the innovator drug)."41
The FDCA places an additional burden on drug
importers by prohibiting the importation of food and
drugs that "appear" to be adulterated or misbranded.42
If FDA field staft at a port of entry determine that an
FDA-regulated product "appears" to be adulterated
or misbranded, the FDA does not admit the product
and issues an Import .Alert (Alert). If an Alert is
issued, identifying a manufacturer, shipper, grower,
importer, or a geographic area, "tuture shipments of
that product ill not be alloxed to enter the United
States, unless thc importer demonstrates that the
product is in compliance wxith the FDGA." 3 Thus,
Alerts transfer thc burden of showxing compliance to
thc importer.44 Furthermore, Alcrts idcntify products
that may be detained based on information other thman
the res'ults a/physical examination of a s'amp/e.45 the
FDA, through its reference manual for FD)A personnel,
has interpreted' "or otherwise"' in the enabling statute 46
to mean ". . a history of the impoitation of xviolative
pioducts, or products that may appear xviolatixve, or
when other information indicates that future entries
may appear violative."47 "Appearance" is not defined
by FDA regulations." By law, the Secretary of the
Department of Health and Human Services (111HS)
holds discretion over the admissibility of FDA-
regulated products offered for import and therefore a
decision to refuse admission is not reviewable under
the Administrative Procedure Act (APA). 49 FDA
regulations do provide for an informal hearing to
contest refusal of admission," but testimony offered by
the owner or consignee of the product is not mandatory
or limiting upon the Secretary.>
ILIportation oft'Unapprovedci
a.n d Im ,a 11.1p o rt ed 1Dru1g S
As noted earlier, foreign versions of FDA approved
drugs and re-imported drugs are considered
unapproved, and thus are prohibited from being
introduced into interstate commerce.> Despite the
narrow and clearly defined legal avenues by which
Americans may legally obtain pharmaceutical drugs
unapproved by the FDA, in 2003 "nearly five million
shipments, comprising about 12 million prescription
drug products with a value of approximately $700
million entered the United States from Canada."
Yet, notwithstanding vigorous legislative efforts to
permit the re-importation of drugs for commercial
use. it remains nonexistent and illegal, despite the
discretion held by the HHS Secretary to waive the
restriction. The current enforcement environment
is less restrictive as to the personal importation of
unapproved drugs, perhaps because of the widely
publicized toll prohibitively expensive drugs place on
many Americans.
A, Perskonal Uprainof
There are two ways that currently make it possible
for an individual to import unapproved drugs into
the United States for personal use: (1) the FDA's
enforcement guidelines for t.S. Custom and Border
Protection (CBP) officers that arguably creates a de
facto exemption for individuals who import or reimport
unapproved drugs for personal use;56 and (2) Section
535 of the 2007 Homeland Securitx Appropriations
Act xwhich piohibits CBP from preventing personal
reimporation of diugs from Canlada.5 Primarily due to
its greater rcsourccs, the CBP is tasked xxith enforcing
the drug laxxs and policies of the FDA and thc Drug
Lnforccment Agency (DLA). 8 These axvenues place
fornmal and informal linmitations on the amount of
unapprosvedt drugs that an individlual can import.
The C ontrolled Substances Act (CSA) also contains
specific provisions which allow idividuals to
travel intemationally with limited quantities of their
prescription medications "if: (1) the substance is found
in one of the approved 'schedules,' (2) the substance
is in its original container., (3) a declaration is made to
the U'nited States Customs Service, and (4) use of such
substance is pennitted by federal and state laws.">5 The
CSA limits the amount of the controlled substance that
can be imported to 50 dosage units of the controlled
substance unless the individual possesses a valid
prescription issued by a practitioner in accordance
with federal and state law6oI he general purpose of
these provisions is to allow patients to only travel with
medication that may be medically necessary for their
health.
The FDCA provides no legal exception for the
importation or re-importation of unapproved drugs,
regardless of whether the importer is an individual
or a business. Notwithstanding the limited exception
to personal re-importation from Canada located
in the 2007 Department of IHomeland Security
Appropriations Act, personal importation or re-
importation of unapproved drugs, remain illegal. In
order to "best protect consumers with a reasonable
expenditure of resources," and perhaps as a recognition
of the potential public backlash for punishing
offenders susceptible to sympathy. the FDA maintains
in its Regulatory Procedure Manual a personal import
policy.> The guidelines permit FDA personnel to "use
their discretion to allow entry of shipments of violative
FDA regulated products when the quantity and purpose
are clearly for personal use, and the product does not
present an unreasonable risk to the user." 1 laborating
this guidance, the manual states that:
In deciding whether to exercise discretion to
allow personal shipments of drugs or devices,
FDA personnel may consider a more permissive
policy in the following situations: (1) when the
intended use is appropriately identified, such
use is not for treatment of a serious condition.
and the product is not known to represent a
significat health risk; and (2) when a) the
intendcd use is unapproxved and for a serious1
conditioni for wich ficefetve treatmnent may
not be available donmesuically either through
commercial or clinical means: b) there is no
knoxi acommnercializa/ion or promotion to
persons residing in the U.S. by those insvolsved
in the distribution of the product at issue; c)
the product is considered not to represent an
an;reas onable risk, and d) the indixidual seeking
to import the pioduct affirms in wxriting that it
is for the patient t own use (generally not more
than 3-month supply) and provides the name
and address of the doctor licensed in the U.S.
responsible for his or her treatment with the
product, or provides evidence that the product
is for the continuation of a treatment begun in a
foreign country.
The guidance does not cover "commercial and
promotional shipments" and lists factors such as "the
type of product, accompanying literature, size, value,
and/or destination of the shipment," that may be
used to distinguish between personal shipments and
"commercial and promotional shipments." 64
Although the FDA's enforcement guidelines have been
said to create a de facto exemption tor individual, non-
commercial importation, the guidance states that it
"should not be interpreted as a license to individuals
to bring in such shipments."" Despite its clear
language, the policy contained in the guidance has
been "widely misunderstood and mischaracterized
as somehow allowing individuals to bring in any
medicines, regardless of the otherwise-applicable
import requirements."66
Section 535 of the 2007 Homeland Security
Appropriations Act prohibits the C3lP from preventing
individuals "not in the business of importing a
prescription drug (within the meaning of section
801(g) of the Federal IFood, Drug, and Cosmetic)
from importing a prescription drug from Canada
that complies i'th the F1ederal Food, Drug, and
Cosmetic Act .... 6 This section essentially permits
the re-importation of drugs from Canada that wiould
otherwise comply with FDA standards. This law does
provide for important limitations for those who seek to
act on this prohibition against enforcement because the
section is only applicable to "individuals transporting
on their person a personal-use of the prescription
drug, not to exceed a 90-day supply ... 'I" hese
qualifications substantially limit individuals who may
exploit this exception to the ban on re-importation.
Only individuals who live near the American-Canadian
border can benefit from this exception due to the
prohibitive cost of traveling from further distances.
B, e1' C ciatIRe ,nmp o r t ation
There are no legal or enforcement exceptions permitting
the importation of foreign-manufacturer drugs for
commercial purposes. There are two conditional
exceptions to the prohibition on re-importation: (1)
the HIlIS Secretary has the authority to authorize re-
importation if the "drug is required for emergency
medical care;" 69 and (2) importation may be allowed
under the Medicare Prescription Drug, Improvement,
and Modernization Act (MMA).0
The Prescription Drug Marketing Act (PDMA) of
1988n amended the importation provision of the
FDCA to prohibit the re-importation of a drug unless
the drug is imported by the manufacturer of the drug.
TFhe PDMA was a result of a series of hearings held
in the mid-1980s by the louse Committee on E nergy
And Commerce "aimed at illuminating flaws in the
U.S. drug distribution system."73 A House oversight
report encapsulated the impetus behind the passage of
the PDMA:
The realities of the wholesale marketplace haxe
combined to create a system in which a large
amount of attractively priced pharmaceuticals
are constantly available,. some of which are
not safe or effective. The physical movement,.
conditions of storage, and. in some cases,
even the origins of much of this merchandise
is unknown to the first, second, or third level
buyer, who in effect plays a forn of Russian
roulette. Ihis situation cannot be allowed to
continue.74
In addition to amending the FDCA to prohibit re-
importation by anyone other than the manufacturer
of the drug, the PDMA also established minimum
federal requirements for the xvholesale distribution of
drugs, including requiring pedigree papers for certain
transactions.
Thle MM A superseded the Medical E-quity Drug
Safety Act, xxhich had similar import proxvisions
to the MMA. The MMA, which became effective
January 1, 2006, was an ambitious and comprehensive
response to the high cost of drugs. Although it is
arIguably incomplete and severely skewed toward the
interests of drug manufactures,76 it did lead to notable
outcomes. The most notable outcome of the MMA was
that it added Part D, the Medicare Prescription Drug
Benefit, to Title XVIII of the Social Security Act. The
program disperses the risk of drug cost by including
private insurance plans that contract with the Federal
government. The drug coverage is provided through
Medicare Advantage prescription drug plans chosen
by Medicare beneficiaries.
Indeed,. Medicare Part D, as it is commonly referred to,
is the most substantial expansion of Medicare ever. Due
to its extension of Medicare benefits to prescription
drugs, research suggests that the MMA may have led to
a decline in importation of drugs from Canada. It has
been allegedthatthe U.S. Government has strengthened
enforcement against personal re-importation in order
to encourage enrollment in Medicare Part D.7
The MMA provides that "The [HHS] Secretary,
after consultation with the United States Trade
Representative and the Commissioner of Customs.
shall promulgate regulations permitting pharmacists
and wholesalers to import prescription drugs from
Canada into the United States."" The MMA then
provides requirements that importers and imported
drugs must comply with. The MMA also contains a
provision allowing the HHIIS Secretary to authorize
waivers for individual importation: "The Secretary
may grant to individuals, by regulation or on a case-by-
case basis, a waiver of the prohibition of importation
of a prescription drug or device or class of prescription
drugs or devices, under such conditions as the Secretary
deterines to be appropriate." IHowever, these
provisions are ineffective until the "Secretary certifies
to the Congress that the implementation of this section
will - (A) pose no additional risk to the public's health
and safety'; and (1B) result in a significant reduction
in the cost of covered products to the American
consumer."" To date, all HHS Secretaries since the
MMA and its predecessor, the Medical Equity Drug
Safety Act became effectixve haxve declined to issue
certification. 83
T he re-import provisions of the MMAN prosvides states
svith an uncertain legal xwindoxw, but a potent political
instrumenlt to moxve forxsard xxith state-sponlsored drug
programs that xxould gixve residents access to cheaper
re-imported dmugs T he MMA prompted states to
petition the HHlS to grant xxaixvers to permit indiv iduals
to re-import drugs from Canada and to issue a
certification permitting the commercial re-importation
of drugs from Canada. As mentioned before, no
waivers or certifications have been issued under MMA
and its predecessor. All state efforts to have the MMA
legitimize their state re-importation efforts through
litigation have also failed. Despite this, states have
continued to operate re-importation programs with the
aid of Canadian pharmacies.84
In 2005S, the Vermont Agency of Administration
submitted a citizen petition to the FDA requesting that
the FDA callow the Vermont State Employee Medical
Benefit Plan (VTSEMBP) to "establish a program
for the orderly individual importation of prescription
medications."" In the petition, the State of Vermont
explained that it wanted:
Authority to contract with providers to create a
system under which its members have the option
of forxarding a prescription to a Canadian firm
where the prescription would be reviewed by a
physician familiar with the member's medical
history and re-written as a Canadian prescrip-
tion, which would be forwarded to a licensed
Canadian pharmacy to be illed and sent by mail
to the member in the United States."
IThe FDA denied this petition.I In ernont ' iLeavitt,8
Vermont alleged that the FDA's refusal of a Vermont's
citizen's petition was "arbitrary and capricious" in
violation of the Administrative Procedure Act (APA)."1
Vermont utilized some creative, yet very unconvincing
applications of statutory interpretation to argue that the
MN authorized their program89 and challenged the
constitutionally of the Act by unsuccessfully invoking
the non-delegation doctrine.9 The Defendants claimed
that they were required to deny the petition because
it proposed a drug importation programx that violated
federal law. in granting the Defendant's motion to
dismiss, the Court held that the MMA could not be
construed to authorize Vermont's importation program
and that the program would violate 21 U.S.C. section
331(t) by "causing" its members to import drugs in
violation of 21 U.S.C. section 381(d)(1)."
A y ear latei in Montgomeryv C ountv, Md. v. L eviltt
NMontgomeiy C ounts, Md. (County) requested a waiver
to allows the residents of the County and its gosvernment
to import drugs from Canada.9 The Counts applied
the same arguments used by V ermont, xxhich yielded
the same results.94
Utndeteired, states hasve persisted in their efforts
to facilitate the puirchase of cheaper foreign drugs.
The most anxbitious state leader xwas former Illinois
Governor Milord R. Blagojevich, xwho created the
web site I-Save RX, which also serves residents of
Wisconsin, Kansas, Missouri, and Vermont.99 I-Saxve
RX uses a Canadian Pharmacy Benetit Management (PBM), which sources
the drugs from Canada, Ireland, the United Kingdom, New Zealand, and
Australia. "Under the program, US prescriptions and medical histories are
forwarded to physicians in the supplying countries, apparently rewritten to
comply with local laws, and dispensed by local, licensed pharmacists who
then ship the medicine to the United States."96 The program only applies
to refills and excludes most drugs that require special handling.97 Former
Governor Blagojevich maintains that, on average, the drugs from these
countries are 25-50% less expensive than in the IUnited States and identical
to the FDA-approved counterpart in every respect other than price. Q
Despite the purported savings the program offers, its aggregate impact
has been minimal. Pharmaceutical companies have sought to obstruct
foreign pharmacies selling to Americans by tightening oversight over their
wholesale distribution99 and the FDA has targeted shipments into the United
States by I-Save RX.100 Moreover, with 27 million eligible residents to
the program fewer than 20,000 orders were placed in its first two years
of operation. Ierhaps its most important (and intended) function is as a
"political symbol."101
kiCone usion
Despite the re-importation-friendly political environment that has likely
emerged from the presidential and congressional elections, the possibility
of a relaxation of restrictions on drug importation and re-importation is
uncertain. As a IU.S Senator, President Barack Obama voted in favor of
legislation that would permit drug re-importation." The Senate and House
of Representatives are currently in the hands of Democrats, who have been
generallx more receptive to re-importation than Republicans. Further, the
recent credit crisis engulfing the global economy, if it precipitates a sustained
economic decline, may pressure Congress to take actions to lower the cost
of healthcare by passing re-importation legislation. Legislation enabling
re-importation is already awaiting action in Congress.103
Yet recent events remind us of the added health risks associated with the
manufacturing of drugs and other FDAregulated products that are not under
the constant regulatory watch of the FDA. The deaths caused by Heparin
manufactured in a Chinese facility104 and the warning letters' 0 and import
alertio6 issued by the FDA to the largest foreign supplier of generic drugs to
the United States, Ranbaxy Laboratories Ltd., for deviations from GMP) in
two of their facilities in Indiaf0 eroded the public's support for re-
importation. Advisors for President Obama express that the IHeparin incident
will make it more challenging to pass reimporation legislation. 0 s L astly,
the influence of the pharmaceutical industry can nexver be underestimated.
WXith billions of (dollars at stake, American phaimaceutical companies xxill
continue their xvigorous lobbxying efforts. It is thus uncertain xxhether the
"invisible hand" xxill proxvide Americans wvith cheaper drugs any time soon.
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